NCT06993675 - Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions

Multiple Myeloma

Interventions

DRUG

Talquetamab

Talquetamab is a GPRC5DxCD3 bispecific antibody. It is supplied as a sterile, preservative-free solution for subcutaneous administration.

DRUG

Teclistamab

Teclistamab is a BCMAxCD3 bispecific antibody. It is supplied as a sterile, preservative-free solution for subcutaneous administration.

Trial Locations (1)

RECRUITING

Yale University, New Haven